Antimicrobial aptamers for detection and inhibition of microbial pathogen growth

Future Microbiology

Volumn 8, Issue 3, 2013, Pages 387-401

  Özalp, Veli Cengiz ^a,b   Bilecen, Kivanc ^a   Kavruk, Murat ^a,b   Avni Öktem, Hüseyin ^a,b  

^a MetuTechnopolis   (Turkey)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

antibiotics; antimicrobial agents; aptamers; biosensors; hygiene monitoring; multidrug resistance; pathogens; riboswitches

Indexed keywords

APTAMER; DEFIBROTIDE; QUERCETIN; ROSEOFLAVIN; UNCLASSIFIED DRUG;

BACILLUS SUBTILIS; COMBINATORIAL CHEMISTRY; ESCHERICHIA COLI; HUMAN; IMMUNOTHERAPY; INFLUENZA VIRUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MICROBIAL GROWTH; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; RIBOSWITCH; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SEROTYPING; VIBRIO CHOLERAE; VIRUS PARTICLE;

ANTI-INFECTIVE AGENTS; APTAMERS, NUCLEOTIDE; BACTERIA; COMMUNICABLE DISEASES; MICROBIOLOGICAL TECHNIQUES; VIRUSES;

EID: 84874740089     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.149     Document Type: Review

References (116)

1. WHO. The 10 Leading Causes of Death by Broad Income Group, 2008. Report no. 310: Fact Sheet. WHO, Switzerland (2008).
2. Hur J, Jawale C, Lee JH. Antimicrobial resistance of Salmonella isolated from food animals: a review. Food Res. Int. 45(2), 819-830 (2012).
3. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis 38(9), 1279-1286 (2004).
4. Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int. J. Antimicrob. Agents 39(4), 295-299 (2012).
5. Silver LL. Challenges of antibacterial discovery. Clin. Microb. Rev. 24(1), 71-109 (2011).
6. Vikesland PJ, Wigginton KR. Nanomaterial enabled biosensors for pathogen monitoring - a review. Environ. Sci. Technol. 44(10), 3656-3669 (2010).
7. Ozalp VC, Nielsen LJ, Olsen LF. An aptamer-based nanobiosensor for real-time measurements of ATP dynamics. Chembiochem 11(18), 2538-2541 (2010).
8. Ozalp VC, Pedersen TR, Nielsen LJ, Olsen LF. Time-resolved measurements of intracellular ATP in the yeast Saccharomyces cerevisiae using a new type of nanobiosensor. J. Biol. Chem. 285(48), 37579-37588 (2010).
9. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287), 818-822 (1990).
10. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968), 505-510 (1990).
11. Marimuthu C, Tang TH, Tominaga J, Tan SC, Gopinath SCB. Single-stranded DNA (ssDNA) production in DNA aptamer generation. Analyst 137(6), 1307-1315 (2012).
12. Kraemer S, Vaught JD, Bock C et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6(10), e26332 (2011).
13. Mayer G, Ahmed MS, Dolf A, Endl E, Knolle PA, Famulok M. Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc. 5(12), 1993-2004 (2010).
14. Cruz-Toledo J, Mckeague M, Zhang X et al. Aptamer base. a collaborative knowledge base to describe aptamers and SELEX experiments. Database (Oxford) 2012, bas006 (2012).
15. Mairal T, Ozalp VC, Lozano Sanchez P, Mir M, Katakis I, O'Sullivan CK. Aptamers: molecular tools for analytical applications. Anal. Bioanal. Chem. 390(4), 989-1007 (2008).
16. Hernandez FJ, Ozalp VC. Graphene and other nanomaterial-based electrochemical aptasensors. Biosensors 2(1), 1-14 (2012).
17. Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery. Pharmaceuticals 4(8), 1137-1157 (2011).
18. Barbas AS, Mi J, Clary BM, White RR. Aptamer applications for targeted cancer therapy. Future Oncol. 6(7), 1117-1126 (2010).
19. Stadler A, Chi C, Van Der Lelie D, Gang O. DNA-incorporating nanomaterials in biotechnological applications. Nanomedicine 5(2), 319-334 (2010).
20. Simmel FC. Towards biomedical applications for nucleic acid nanodevices. Nanomedicine 2(6), 817-830 (2007).
21. Kim Y, Liu C, Tan W. Aptamers generated by cell SELEX for biomarker discovery. Biomark. Med. 3(2), 193-202 (2009).
22. Cibiel A, Dupont DM, Ducongé F. Methods to identify aptamers against cell surface biomarkers. Pharmaceuticals 4(9), 1216-1235 (2011).
23. Hamula CLA, Zhang H, Li F, Wang Z, Le XC, Li X-F. Selection and analytical applications of aptamers binding microbial pathogens. Trends Anal. Chem. 30(10), 1587-1597 (2011).
24. Dwivedi H, Smiley RD, Jaykus L-A. Selection and characterization of DNA aptamers with binding selectivity to Campylobacter jejuni using whole-cell SELEX. Appl. Microbiol. Biotechnol. 87(6), 2323-2334 (2010).
25. Lee YJ, Han SR, Maeng JS, Cho YJ, Lee SW. In vitro selection of Escherichia coli O157:H7-specific RNA aptamer. Biochem. Biophys. Res. Comm. 417(1), 414-420 (2012).
26. Li H, Ding XH, Peng ZH et al. Aptamer selection for the detection of Escherichia coli K88. Can. J. Microbiol. 57(6), 453-459 (2011).
27. Bruno JG, Carrillo MP, Phillips T. In vitro antibacterial effects of antilipopolysaccharide DNA aptamer-C1qrs complexes. Folia Microbiol. (Praha) 53(4), 295-302 (2008).
28. Liu GQ, Yu XF, Xue F et al. Screening and preliminary application of a DNA aptamer for rapid detection of Salmonella O8. Microchim. Acta 178(1-2), 237-244 (2012).
29. Hyeon J-Y, Chon J-W, Choi I-S, Park C, Kim D-E, Seo K-H. Development of RNA aptamers for detection of Salmonella enteritidis. J. Microbiol. Methods 89(1), 79-82 (2012).
30. Joshi R, Janagama H, Dwivedi HP et al. Selection, characterization, and application of DNA aptamers for the capture and detection of Salmonella enterica serovars. Mol. Cell. Probes 23(1), 20-28 (2009).
31. Pan Q, Zhang XL, Wu HY et al. Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrob. Agents Chem. 49(10), 4052-4060 (2005).
32. Duan N, Wu S, Chen X, Huang Y, Wang Z. Selection and identification of a DNA aptamer targeted to Vibrio parahemolyticus. J. Agricult. Food Chem. 60(16), 4034-4038 (2012).
33. Ohk SH, Koo OK, Sen T, Yamamoto CM, Bhunia AK. Antibody-aptamer functionalized fibre-optic biosensor for specific detection of Listeria monocytogenes from food. J. Appl. Microbiol. 109(3), 808-817 (2010).
34. Cao X, Li S, Chen L et al. Combining use of a panel of ssDNA aptamers in the detection of Staphylococcus aureus. Nucleic Acids Res. 37(14), 4621-4628 (2009).
35. Hamula CL, Le XC, Li XF. DNA aptamers binding to multiple prevalent M-types of Streptococcus pyogenes. Anal. Chem. 83(10), 3640-3647 (2011).
36. Bruno J, Carrillo M. Development of aptamer beacons for rapid presumptive detection of Bacillus spores. J. Fluoresc. 22(3), 915-924 (2012).
37. Labib M, Zamay AS, Muharemagic D, Chechik AV, Bell JC, Berezovski MV. Aptamer-based viability impedimetric sensor for viruses. Anal. Chem. 84(4), 1813-1816 (2012).
38. Park SY, Kim S, Yoon H et al. Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Ther. 21(6), 395-402 (2011).
39. Choi S, Lee C, Lee K et al. DNA aptamers against the receptor binding region of hemagglutinin prevent avian influenza viral infection. Mol. Cell 32(6), 527-533 (2011).
40. Gopinath SCB, Hayashi K, Kumar PKR. Aptamer that binds to the gD protein of herpes simplex virus-1 and efficiently inhibits viral entry. J. Virol. 86(12), 6732-6744 (2012).
41. Moore MD, Bunka DHJ, Forzan M et al. Generation of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides. J. Gen. Virol. 92(7), 1493-1499 (2011).
42. Khati M, Schüman M, Ibrahim J, Sattentau Q, Gordon S, James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2́F-RNA aptamers. J. Virol. 77(23), 12692-12698 (2003).
43. Zhou JH, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21(1), 1-10 (2011).
44. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45(9), 1628-1650 (1999).
45. Luebbecke M, Walter J-G, Stahl F, Scheper T. Aptamers as detection molecules on reverse phase protein microarrays for the analysis of cell lysates. Eng. Life Sci. 12(2), 144-151 (2012).
46. Liss M, Petersen B, Wolf H, Prohaska E. An aptamer-based quartz crystal protein biosensor. Anal. Chem. 74(17), 4488-4495 (2002).
47. Deng Q, Watson CJ, Kennedy RT. Aptamer affinity chromatography for rapid assay of adenosine in microdialysis samples collected in vivo. J. Chromatogr. A 1005(1-2), 123-130 (2003).
48. Boisgard R, Kuhnast B, Vonhoff S et al. In vivo biodistribution and pharmacokinetics of F-18-labelled Spiegelmers. A new class of oligonucleotidic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 32(4), 470-477 (2005).
49. Padilla R, Sousa R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2́-groups using a mutant T7 RNA polymerase (RNAP). Nucleic Acids Res. 27(6), 1561-1563 (1999).
50. Kubik MF, Bell C, Fitzwater T, Watson SR, Tasset DM. Isolation and characterization of 2́-fluoro-, 2́-amino-, and 2́-fluoro/ amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. J. Immunol. 159(1), 259-267 (1997).
51. Kujau MJ, Wolfl S. Intramolecular derivatization of 2́-amino- pyrimidine modified RNA with functional groups that is compatible with re-amplification. Nucleic Acids Res. 26(7), 1851-1853 (1998).
52. Hernandez FJ, Kalra N, Wengel J, Vester B. Aptamers as a model for functional evaluation of LNA and 2́-amino LNA. Bioorg. Med. Chem. Lett. 19(23), 6585-6587 (2009).
53. Veedu RN, Wengel J. Locked nucleic acid nucleoside triphosphates and polymerases: on the way towards evolution of LNA aptamers. Mol. Biosyst. 5(8), 787-792 (2009).
54. Zwanikken JW, Guo P, Mirkin CA, Olvera de la Cruz M. Local ionic environment around polyvalent nucleic acid-functionalized nanoparticles. J. Phys. Chem. C 115(33), 16368-16373 (2011).
55. Sutcliffe JA. Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol. 8(5), 534-542 (2005).
56. Breaker RR. Riboswitches: from ancient gene-control systems to modern drug targets. Future Microbiol. 4(7), 771-773 (2009).
57. Deigan KE, Ferré-D'Amaré AR. Riboswitches: discovery of drugs that target bacterial gene-regulatory RNAs. Acc. Chem. Res. 44(12), 1329-1338 (2011).
58. Edwards AL, Batey RT. Riboswitches: a common RNA regulatory element. Nature Educ. 3(9), 9 (2010).
59. Sudarsan N, Cohen-Chalamish S, Nakamura S, Emilsson GM, Breaker RR. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. Chem. Biol. 12(12), 1325-1335 (2005).
60. Lee ER, Blount KF, Breaker RR. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol. 6(2), 187-194 (2009).
61. Kim JN, Blount KF, Puskarz I, Lim J, Link KH, Breaker RR. Design and antimicrobial action of purine analogues that bind guanine riboswitches. ACS Chem. Biol. 4(11), 915-927 (2009).
62. Huang L, Ishibe-Murakami S, Patel DJ, Serganov A. Long-range pseudoknot interactions dictate the regulatory response in the tetrahydrofolate riboswitch. Proc. Natl Acad. Sci. USA 108(36), 14801-14806 (2011).
63. Lunse CE, Schmidt MS, Wittmann V, Mayer GN. Carba-sugars activate the glmS-riboswitch of Staphylococcus aureus. ACS Chem. Biol. 6(7), 675-678 (2011).
64. Planson A-G, Carbonell P, Grigoras I, Faulon JL. A retrosynthetic biology approach to therapeutics: from conception to delivery. Curr. Opin. Biotechnol. 23(6), 948-956 (2012).
65. Blum JH, Dove SL, Hochschild A, Mekalanos JJ. Isolation of peptide aptamers that inhibit intracellular processes. Proc. Natl Acad. Sci. USA 97(5), 2241-2246 (2000).
66. Jin Y, Huang J-D. Engineering a portable riboswitch-LacP hybrid device for two-way gene regulation. Nucleic Acids Res. 39(19), e131 (2011).
67. Feng X, Liu L, Duan X, Wang S. An engineered riboswitch as a potential gene-regulatory platform for reducing antibacterial drug resistance. Chem. Comm. 47(1), 173-175 (2011).
68. Fujita Y, Tanaka T, Furuta H, Ikawa Y. Functional roles of a tetraloop/receptor interacting module in a cyclic di-GMP riboswitch. J. Biosci. Bioeng. 113(2), 141-145 (2012).
69. European CDC/European Medicines Agency Joint Working Group. The Bacterial Challenge: Time to React. European CDC, Sweden (2009).
70. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
71. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7(5), 459-469 (2007).
72. Schlesinger SR, Lahousse MJ, Foster TO, Kim SK. Metallo-b-lactamases and aptamer-based inhibition. Pharmaceuticals 4(2), 419-428 (2011).
73. Shum KT, Lui ELH, Wong SCK et al. Aptamer-mediated inhibition of Mycobacterium tuberculosis polyphosphate kinase 2. Biochemistry 50(15), 3261-3271 (2011).
74. Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu. Rev. Biochem. 78, 605-647 (2009).
75. Joshi P, Prasad VR. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J. Virol. 76(13), 6545-6557 (2002).
76. Held DM, Kissel JD, Saran D, Michalowski D, Burke DH. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J. Biol. Chem. 281(35), 25712-25722 (2006).
77. Hannoush RN, Min K-L, Damha MJ. Diversity-oriented solid-phase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors. Nucleic Acids Res. 32(21), 6164-6175 (2004).
78. Mescalchin A, Restle T. Oligomeric nucleic acids as antivirals. Molecules 16(2), 1271-1296 (2011).
79. Ramalingam D, Duclair S, Datta SA, Ellington A, Rein A, Prasad VR. RNA aptamers directed to human immunodeficiency virus type 1 gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J. Virol. 85(1), 305-314 (2011).
80. Francischetti IMB, Oliveira CJ, Ostera GR et al. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler. Thromb. Vasc. Biol. 32(3), 786-798 (2012).
81. Sabbagh SC, Forest CG, Lepage C, Leclerc JM, Daigle F. So similar, yet so different: uncovering distinctive features in the genomes of Salmonella enterica serovars typhimurium and typhi. FEMS Microbiol. Lett. 305(1), 1-13 (2010).
82. Li H, Ding X, Peng Z et al. Aptamer selection for the detection of Escherichia coli K88. Can. J. Microbiol. 57(6), 453-459 (2011).
83. Chen F, Hu Y, Li D, Chen H, Zhang X-L. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 4(12), e8142 (2009).
84. Feng H, Beck J, Nassal M, Hu KH. A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication. PLoS One 6(11), e27862 (2011).
85. Chen F, Zhang X, Zhou J, Liu S, Liu J. Aptamer inhibits Mycobacterium tuberculosis (H37Rv) invasion of macrophage. Mol. Biol. Rep. 39(3), 2157-2162 (2012).
86. Punnarak P, Santos M, Hwang S et al. RNA aptamers inhibit the growth of the fish pathogen viral hemorrhagic septicemia virus (VHSV). Mar. Biotechnol. (NY) 14(6), 752-761 (2012).
87. Bruno JG. Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells. In vitro Cell. Dev. Biol. Anim. 46(2), 107-113 (2010).
88. Hwang S-Y, Sun H-Y, Lee K-H et al. 5́-triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity. Nucleic Acids Res. 40(6), 2724-2733 (2012).
89. Chang YC, Kao WC, Wang WY, Wang WY, Yang RB, Peck K. Identification and characterization of oligonucleotides that inhibit toll-like receptor 2-associated immune responses. FASEB J. 23(9), 3078-3088 (2009).
90. Gardner S, Jaing C, Mcloughlin K, Slezak T. A microbial detection array (MDA) for viral and bacterial detection. BMC Genomics 11(1), 668 (2010).
91. Karkkainen RM, Drasbek MR, Mcdowall I, Smith CJ, Young NWG, Bonwick GA. Aptamers for safety and quality assurance in the food industry: detection of pathogens. Int. J. Food Sci. Technol. 46(3), 445-454 (2011).
92. Dwivedi HP, Jaykus L-A. Detection of pathogens in foods: the current state-of-the-art and future directions. Crit. Rev. Microbiol. 37(1), 40-63 (2011).
93. Driscoll M, Ramsay C, Watkin J. Improved sensitivity method for rapid hygiene monitoring using ATP bioluminescence. Luminescence 21(5), 274-275 (2006).
94. Fukuba T, Aoki Y, Fukuzawa N, Yamamoto T, Kyo M, Fujii T. A microfluidic in situ analyzer for ATP quantification in ocean environments. Lab Chip 11(20), 3508-3515 (2011).
95. Moore G, Griffith C. A comparison of traditional and recently developed methods for monitoring surface hygiene within the food industry: an industry trial. Int. J. Environ. Health Res. 12(4), 317-329 (2002).
96. Aiken ZA, Wilson M, Pratten J. Evaluation of ATP bioluminescence assays for potential use in a hospital setting. Infect. Control Hosp. Epidemiol. 32(5), 507-509 (2011).
97. Carrascosa C, Saavedra P, Millán R et al. Monitoring of cleanliness and disinfection in dairies. Comparison of traditional microbiological and ATP bioluminescence methods. Food Control (28)2, 368-373 (2012).
98. Ozalp VC. Acoustic quantification of ATP using a quartz crystal microbalance with dissipation. Analyst 136(23), 5046-5050 (2011).
99. Ozalp VC. Dual-polarization interferometry for quantification of small molecules using aptamers. Anal. Bioanal. Chem. 402(2), 799-804 (2012).
100. Anjum MF, Tucker JD, Sprigings KA, Woodward MJ, Ehricht R. Use of miniaturized protein arrays for Escherichia coli O serotyping. Clin. Vaccine Immunol. 13(5), 561-567 (2006).
101. Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int. Suppl. 75(112), S4-S7 (2009).
102. Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular insight into invasive group A streptococcal disease. Nat. Rev. Microbiol. 9(10), 724-736 (2011).
103. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J. Clin. Microbiol. 34(4), 953-958 (1996).
104. Musser JM, Kapur V, Szeto J, Pan X, Swanson DS, Martin DR. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect. Immun. 63(3), 994-1003 (1995).
105. Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan B. Salmonella nomenclature. J. Clin. Microbiol. 38(7), 2465-2467 (2000).
106. Zelada-Guillen GA, Bhosale SV, Riu J, Rius FX. Real-time potentiometric detection of bacteria in complex samples. Anal. Chem. 82(22), 9254-9260 (2010).
107. Duan N, Wu S, Zhu C et al. Dual-color upconversion fluorescence and aptamer-functionalized magnetic nanoparticles-based bioassay for the simultaneous detection of Salmonella typhimurium and Staphylococcus aureus. Anal. Chim. Acta 723, 1-6 (2012).
108. Singh G, Vajpayee P, Rani N, Jyoti A, Gupta KC, Shanker R. Bio-capture of S. typhimurium from surface water by aptamer for culture-free quantification. Ecotoxicol. Environ. Saf. 78, 320-326 (2012).
109. Jyoti A, Vajpayee P, Singh G, Patel CB, Gupta KC, Shanker R. Identification of environmental reservoirs of nontyphoidal salmonellosis: aptamer-assisted bioconcentration and subsequent detection of Salmonella typhimurium by quantitative polymerase chain reaction. Environ. Sci. Technol. 45(20), 8996-9002 (2011).
110. Lee H-J, Kim BC, Kim K-W, Kim YK, Kim J, Oh M-K. A sensitive method to detect Escherichia coli based on immunomagnetic separation and real-time PCR amplification of aptamers. Biosens. Bioelectron. 24(12), 3550-3555 (2009).
111. Book B, Chen J, Irudayaraj J. Quantification of receptor targeting aptamer binding characteristics using single-molecule spectroscopy. Biotechnol. Bioeng. 108(5), 1222-1227 (2011).
112. Ravindranath SP, Wang Y, Irudayaraj J. SERS driven cross-platform based multiplex pathogen detection. Sens. Actuators B Chem. 152(2), 183-190 (2011).
113. Negri P, Chen G, Kage A et al. Direct optical detection of viral nucleoprotein binding to an anti-influenza aptamer. Anal. Chem. 84(13), 5501-5508 (2012).
114. Nitsche A, Kurth A, Dunkhorst A et al. One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol. 7(1), 48-60 (2007).
115. Negri P, Kage A, Nitsche A, Naumann D, Dluhy RA. Detection of viral nucleoprotein binding to anti-influenza aptamers via SERS. Chem. Comm. 47(30), 8635-8637 (2011).
116. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 50(1), 237-257 (2010).